Description
An agonist of TRβ (EC50s = 0.21 and 3.74 µM for TRβ and TRα, respectively); inhibits hERG channels (IC50 = 30 µM); liver-directed, with a liver to plasma ratio of 8:1 to reduce systemic exposure; does not affect the expression of α-MHC in a rat model of hypothyroidism, an effect mediated by TRα; lowers non-HDL cholesterol and liver triglycerides without affecting Tsh levels in rat and rabbit models of hypercholesterolemia; lowers plasma glucose levels and improves insulin sensitivity in DIO mice
Formal name: 2-[3,5-dichloro-4-[[1,6-dihydro-5-(1-methylethyl)-6-oxo-3-pyridazinyl]oxy]phenyl]-2,3,4,5-tetrahydro-3,5-dioxo-1,2,4-triazine-6-carbonitrile
Synonyms:
Molecular weight: 435.2
CAS: 920509-32-6
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Ion Channel Modulation|Blockers||Product Type|Biochemicals|Receptor Pharmacology|Agonists||Research Area|Cardiovascular System|Lipids & Lipoproteins|Lipoproteins||Research Area|Endocrinology & Metabolism|Hormones & Receptors|Thyroid Hormones||Research Area|Endocrinology & Metabolism|Inborn Errors of Metabolism||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Dyslipidemias||Research Area|Endocrinology & Metabolism|Metabolic Diseases|NAFLD & NASH